-0.16%
-1.64%
6.93%
22.24%
116.55%
114.78%
127.55%
AI Spotlight on UCB
Company Description
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases.The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus.
In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease.Further, it engages in contract manufacturing activities.UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai.
It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally.The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Market Data
| Last Price | 189.05 |
| Change Percentage | -0.16% |
| Open | 189.35 |
| Previous Close | 189.35 |
| Market Cap ( Millions) | 35867 |
| Volume | 63629 |
| Year High | 198.95 |
| Year Low | 85.76 |
| M A 50 | 186.54 |
| M A 200 | 159.77 |
Financial Ratios
| FCF Yield | 1.60% |
| Dividend Yield | 0.72% |
| ROE | 2.68% |
| Debt / Equity | 33.93% |
| Net Debt / EBIDTA | 220.25% |
| Price To Book | 4.01 |
| Price Earnings Ratio | 149.54 |
| Price To FCF | 62.69 |
| Price To sales | 6.57 |
| EV / EBITDA | 32.46 |
News
- Jan -16 - UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
- Dec -27 - USNA or UCBJY: Which Is the Better Value Stock Right Now?
- Dec -19 - Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage Study
- Dec -06 - UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
- Nov -26 - UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
- Nov -20 - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
- Nov -20 - UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
- Nov -19 - Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
- Nov -14 - New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
- Oct -08 - Biotech UCB Mimics Obesity Drug Stocks With Skin Disease Focus
- Sep -30 - UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
- Sep -27 - UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
- Sep -25 - UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
- Sep -24 - Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
- Sep -24 - UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
- Sep -23 - UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
- Aug -29 - Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
- Aug -22 - Belgium stocks higher at close of trade; BEL 20 up 0.33%
- Aug -21 - Belgium stocks higher at close of trade; BEL 20 up 0.73%
- Aug -19 - Best Momentum Stock to Buy for August 19th
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biopharmaceuticals
Expected Growth : 10 %
What the company do ?
UCB SA's Biopharmaceuticals segment focuses on developing and commercializing innovative medicines for severe diseases, including immunology and neurology treatments.
Why we expect these perspectives ?
UCB SA's biopharmaceuticals segment growth is driven by increasing demand for immunology and neurology treatments, strong pipeline of innovative products, strategic partnerships, and expansion into emerging markets. Additionally, growing awareness of chronic diseases and investments in research and development contribute to the 10% growth rate.
Ucb Sa Products
| Product Range | What is it ? |
|---|---|
| Neurology Products | UCB SA develops and commercializes innovative neurology products to treat conditions such as epilepsy, Parkinson's disease, and multiple sclerosis. |
| Immunology Products | UCB SA offers a range of immunology products to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. |
| Bone and Joint Health Products | UCB SA develops and commercializes products to treat bone and joint health conditions such as osteoporosis and osteoarthritis. |
| Respiratory Products | UCB SA offers a range of respiratory products to treat conditions such as asthma and chronic obstructive pulmonary disease (COPD). |
| Inflammation Products | UCB SA develops and commercializes products to treat inflammatory conditions such as inflammatory bowel disease and psoriasis. |
UCB SA's Porter Forces
Threat Of Substitutes
UCB SA operates in a highly competitive market, and there are many substitutes available to customers. However, the company's strong brand reputation and high-quality products help to mitigate the threat of substitutes.
Bargaining Power Of Customers
UCB SA's customers have a high bargaining power due to the availability of substitutes and the company's dependence on a few large customers. This gives customers the power to negotiate prices and terms.
Bargaining Power Of Suppliers
UCB SA has a diverse supplier base, and the company is not heavily dependent on any single supplier. This reduces the bargaining power of suppliers.
Threat Of New Entrants
The threat of new entrants is moderate due to the high barriers to entry in the pharmaceutical industry. However, UCB SA's strong brand reputation and established distribution networks make it difficult for new entrants to gain a foothold.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, and UCB SA faces intense rivalry from established players. The company must continually innovate and invest in R&D to stay ahead of the competition.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 24.55% |
| Debt Cost | 5.83% |
| Equity Weight | 75.45% |
| Equity Cost | 5.83% |
| WACC | 5.83% |
| Leverage | 32.53% |
UCB SA : Quality Control
UCB SA passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who … |
| NOVO-B.CO | Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. … |
| ARGX.BR | argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead … |
| REGN | Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular … |
| GSK.L | GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Vertex Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
GSK
A-Score
1-Year Total Return ->
🥉
Regeneron Pharmaceuticals
A-Score
1-Year Total Return ->
4
Novo Nordisk
A-Score
1-Year Total Return ->
5
UCB
A-Score
1-Year Total Return ->
6
